Biotech & Pharma.T.A, Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A,

BIB 77.91

+1.5%

Nov 18 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jibacoa who wrote (78)	10/22/2002 11:10:38 PM
From: Jibacoa	Read Replies (1) of 3722

JNJ and the coated stent market. Well in spite of closing to the downside today, it is likely that JNJ will bounce back tomorrow after an FDA advisory panel today unanimously endorsed its Sirulimus-coated stent. JNJ said they expect approval of their Cypher stent by the end of the first Q in 2003. Analysts predict that the drug-coated stents will double the size of the overall coronary stent market to $5 billion. It is expected that J&J will be alone in the drug-coated stent market for a full year because BSX is not expected to bring its paclitaxel-coated stent to the U.S. market before the end of 2003.JNJ is already marketing its Cypher stent in Europe. biz.yahoo.com siliconinvestor.com siliconinvestor.com BSX has been outperforming JNJ and GDT in the last 3 months. siliconinvestor.com Bernard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next